Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aura Biosciences Inc (AURA)
NASDAQ:AURA
RESEARCH TOOLSreports
Aura Biosciences Inc (AURA) Stock Price & Analysis
82 Followers
AURA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.99 - $13.50
Previous Close$7.22
Volume116.07K
Average Volume (3M)182.83K
Market Cap
$357.63M
Enterprise Value$151.04M
Total Cash (Recent Filing)$226.15M
Total Debt (Recent Filing)$19.56M
Price to Earnings (P/E)-3.7
Beta1.39
Next Earnings
May 09, 2024EPS Estimate
-$0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding49,504,405
10 Day Avg. Volume118,103
30 Day Avg. Volume182,833
Standard Deviation0.16
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.55
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.66
Forecast
1Y Price Target
$19.75Price Target Upside173.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Aura Biosciences Inc News
PremiumCompany Announcements
Raj Parekh to Exit Board at Aura Biosciences’ Meeting
Bulls Say, Bears Say
Bulls Say
Market OpportunityBel-sar could become the first approved treatment for primary choroidal melanoma, representing a significant market opportunity.
Regulatory ConfidenceThe FDA's special protocol assessment agreement for CoMpass indicates a stable trial design, increasing confidence in bel-sar's regulatory approval process.
Trial Design And ExecutionThe simplified primary endpoint in the Phase 3 trial of bel-sar is designed to facilitate smoother regulatory submissions to the FDA and EMA.
Bears Say
Analyst's RatingAnalyst decreases the price target to $21 to reflect the recent updates and extended timeline.
Product DevelopmentPhase 3 completion is more likely to occur in 2026, pushing the estimated launch into 2027.
Stock ValuationThe price target for AURA has been lowered to $21 from $38 after updating the model to reflect recent follow-on offering and forecasted launch delays.
---
Ownership Overview
16.93% Insiders
19.38% Mutual Funds
12.52% Other Institutional Investors
51.18% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $5.99 and its highest was $13.50 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Currently, no data Available
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is May 09, 2024 which is in 11 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on Mar 27, 2024. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.421 by -$0.089.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -$0.49.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 49,533,016 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.421. Following the earnings report the stock price went up 0.917%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Among the largest hedge funds holding Aura Biosciences Inc’s share is Matrix Capital Management Company, LP. It holds Aura Biosciences Inc’s shares valued at 61M.
---
Aura Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (173.55% Upside)
$19.75 (173.55% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 23.8%
Last 30 Days ▲ 23.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.77%
12-Months-Change
Fundamentals
Return on Equity
-36.26%
Trailing 12-Months
Asset Growth
13.91%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.
---
AURA Stock 12 Months Forecast
Average Price Target
$19.75
▲(173.55% Upside)
Technical Analysis
Best Analysts Covering AURA
1 Year
1 Year Success Rate
0/14 ratings generated profit
1 Year Average Return
-25.64%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -25.64% per trade.
---